Research Topics
| I F TannockSummaryAffiliation: University of Toronto Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Eradication of a disease: how we cured symptomless prostate cancerIan F Tannock
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada M5G 2M9
Lancet 359:1341-2. 2002
Mathematics in the realm of lapatinib: 500 + 500 = 1,500?Bostjan Seruga
J Clin Oncol 26:2940-2. 2008
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenograftsLicun Wu
Department of Medical Oncology and Hematology and Division of Experimental Therapeutics, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Cancer Res 65:2825-31. 2005..Our results suggest that repopulation of PTEN-negative cancer cells between courses of chemotherapy might be inhibited by CCI-779...
Repopulation of cancer cells during therapy: an important cause of treatment failureJohn J Kim
Department of Radiation Oncology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada
Nat Rev Cancer 5:516-25. 2005..Strategies developed to overcome repopulation have improved clinical outcomes, and now new strategies to inhibit repopulation are emerging in parallel with advances in the understanding of underlying biological mechanisms...
Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessmentFiona P Downie
Department of Hematology and Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
Psychooncology 15:921-30. 2006..Formal tests such as the HSCS may fail to adequately capture the perceived impact of symptoms...
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumorsKrupa J Patel
Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
BMC Cancer 9:356. 2009..Here we evaluate the effect of PgP expression on doxorubicin distribution in vivo...
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumorsCarol M Lee
Divisions of Applied Molecular Oncology and Medical Oncology and Hematology Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
BMC Cancer 10:255. 2010..Poor distribution of some anticancer drugs in solid tumors may limit their anti-tumor activity...
Collaborative clinical trials: quality or quantity?I F Tannock
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
Int J Radiat Oncol Biol Phys 49:339-43. 2001..Ultimately, strategies that may be individualized among a group of patients with histologically similar tumors will need to be evaluated against the current standard (and homogeneous) treatment...
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerIan F Tannock
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
N Engl J Med 351:1502-12. 2004..We compared such treatment with docetaxel plus prednisone in men with this disease...
Tumor physiology and drug resistanceI F Tannock
Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, ON, Canada
Cancer Metastasis Rev 20:123-32. 2001....
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapyIan F Tannock
Department of Medical Oncology and Hematology and the Division of Experimental Therapeutics, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, M5G 2M9 Canada
Clin Cancer Res 8:878-84. 2002....
Cognitive impairment associated with chemotherapy for cancer: report of a workshopIan F Tannock
Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
J Clin Oncol 22:2233-9. 2004....
When are "positive" clinical trials in oncology truly positive?Alberto Ocana
Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
J Natl Cancer Inst 103:16-20. 2011....
Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trialsBostjan Seruga
Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
J Clin Oncol 29:174-85. 2011..Here, we analyze adverse drug reactions (ADRs) of targeted anticancer agents from updated drug labels and their reporting in corresponding pivotal RCTs...
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end pointsI F Tannock
Department of Medicine, Princess Margaret Hospital, Toronto, Canada
J Clin Oncol 14:1756-64. 1996..To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant end points of palliation in a randomized controlled trial...
The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effectsM Yamagata
Department of Medicine, Ontario Cancer Institute, University of Toronto, Canada
Br J Cancer 73:1328-34. 1996..002 at tolerated doses of the four drugs used to treat KHT tumours. The experiments demonstrate the activity of drugs that inhibit the regulation of pHi against murine tumours when delivered by chronic infusion...
Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapyJ Luo
Department of Medicine, Ontario Cancer Institute, Toronto, Canada
Br J Cancer 70:617-24. 1994..Acid-mediated therapy can lead to cell death in murine solid tumours, but further measures will be required before the strategy can be exploited clinically...
A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancerA J Dowling
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Ontario, Canada
Ann Oncol 12:773-8. 2001..PSA response was associated with longer survival. Patients treated with M + P were more likely to achieve a PSA response and a palliative response than those treated with P...
Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled studyH G Mar Fan
Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Ann Oncol 21:983-7. 2010..Women with breast cancer frequently undergo menopause following adjuvant chemotherapy. Here, we investigated whether they have more severe symptoms than women undergoing natural menopause...
Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugsI F Tannock
Dept of Medical Oncology and Haematology and the Division of Experimental Therapy, Ontario Cancer Institute and Princess Margaret Hospital, University of Toronto, Toronto, Canada
Br J Cancer 84:100-5. 2001..When apoptosis is observed following treatment with anti-cancer drugs it may be a secondary event which occurs in lethally-damaged cells, leading to their lysis, rather than a primary event that leads to loss of reproductive integrity...
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versaD R Berthold
Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Ann Oncol 19:1749-53. 2008..At progression, many patients were treated with the other drug. Here, we provide a retrospective report of survival and prostate-specific antigen (PSA) response after second-line therapy...
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancerP P Leung
Department of Pharmaceutical Services, Ontario Cancer Institute Princess Margaret Hospital, Toronto, Ontario, Canada
J Clin Oncol 17:3082-90. 1999..A cost-utility analysis was therefore performed to create a rank order on the basis of effectiveness, quality of life, and economic considerations...
Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironmentA R Karuri
Division of Experimental Therapeutics, Ontario Cancer Institute, Toronto, Canada
Br J Cancer 68:1080-7. 1993..Weak acids that are normal cellular metabolites are not toxic in vivo, but weak acids carrying cytotoxic groups offer the potential for selective uptake and toxicity under the conditions of low pHe that exist in many solid tumours...
Global drug development in cancer: a cross-sectional study of clinical trial registriesB Seruga
Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
Ann Oncol 21:895-900. 2010..Correlations were sought between the number of clinical trials and incidence, mortality and prevalence of the cancers studied (obtained from GLOBOCAN 2002) and stratified by region of the world...
Factors that influence the penetration of methotrexate through solid tissueD S Cowan
Department of Medicine, Ontario Cancer Institute and University of Toronto, Ontario, Canada
Int J Cancer 91:120-5. 2001..Our data provide evidence that tissue penetration of methotrexate is through the extracellular space, that its distribution in solid tissue may be limited and that it may be possible to improve its tissue penetration...
Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetrationC M Lee
Division of Applied Molecular Oncology, Princess Margaret Hospital University of Toronto, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
Br J Cancer 94:863-9. 2006..We conclude that modifiers of endosomal pH might increase therapeutic effectiveness of basic drugs by increasing their toxicity and/or tissue penetration in solid tumours...
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyDominik R Berthold
FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
J Clin Oncol 26:242-5. 2008..Here, we report an updated analysis of survival...
Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancerF Joly
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
J Urol 176:2443-7. 2006..We compared physical and cognitive function, and quality of life in a cross-sectional study of 57 patients receiving androgen deprivation therapy for nonmetastatic prostate cancer and 51 healthy age matched controls...
The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancerH G Mar Fan
Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Psychooncology 18:156-61. 2009..Here, we report a non-randomized sub-study in which cognitive function of participants was evaluated at 12-30 months after chemotherapy...
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancerB Seruga
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
Ann Oncol 21:1411-8. 2010..Phase III randomized clinical trials (RCTs) have become larger and are powered to detect small absolute benefits. Temporal changes in absolute benefits of experimental medical therapies reported in RCTs are unknown...
Death of tumor cells after intracellular acidification is dependent on stress-activated protein kinases (SAPK/JNK) pathway activation and cannot be inhibited by Bcl-2 expression or interleukin 1beta-converting enzyme inhibitionB W Zanke
Department of Medicine, The Princess Margaret Hospital and the Ontario Cancer Institute, Toronto, Canada
Cancer Res 58:2801-8. 1998..We conclude that acid-induced cell death depends on bax and on SAPK signaling pathways, but not on the caspase proteases. Therapeutic manipulation of bax and SAPK may enhance acid-induced tumor cell killing...
Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapyR P Maidorn
Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Canada
Br J Cancer 67:297-303. 1993....
Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumoursM J Boyer
Department of Medicine, Ontario Cancer Institute, Toronto, Canada
Br J Cancer 68:890-7. 1993..Our results suggest the feasibility of pharmacological inhibition of Na+/H+ exchange activity as an approach to therapy directed against nutrient-deprived tumour cells...
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancerM J Moore
Princess Margaret Hospital, Toronto, Ontario, Canada
J Clin Oncol 15:3441-5. 1997..To evaluate the efficacy and toxicity of gemcitabine (2',2'-difluorodeoxycytidine) in previously untreated patients with advanced transitional cell carcinoma...
Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and costS A McLachlan
Department of Medicine, Ontario Cancer Institute Princess Margaret Hospital, Toronto, Canada
Breast Cancer Res Treat 54:213-23. 1999....
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinomaC Mayers
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Cancer 91:2246-57. 2001..Classic CMF should be used when this regimen is selected for adjuvant treatment, and dose adjustment resulting in moderate myelosuppression should be explored in future clinical trials...
Is there a role for chemotherapy in prostate cancer?C M Canil
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
Br J Cancer 91:1005-11. 2004..Large phase III trials comparing docetaxel with mitoxantrone have completed accrual. There is no role for chemotherapy in earlier stages of disease except in the context of a well-designed clinical trial...
Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot studyA J Davis
Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Cytometry A 51:1-6. 2003..CONCLUSIONS: Our results did not suggest an increase in proliferation of tumor cells after this type of chemotherapy in the majority of patients with ovarian cancer...
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancerNadine Tchen
Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
J Clin Oncol 21:4175-83. 2003..CONCLUSION: Adjuvant chemotherapy causes cognitive dysfunction, fatigue, and menopausal symptoms in women with breast cancer. Priority should be given to the study of strategies that might reduce these toxic effects...
Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimenNeil Isaac
Department of Radiation Oncology, Princess Margaret Hospital/University Health Network and University of Toronto, Toronto, Ontario, Canada
Cancer 95:696-703. 2002..22). CONCLUSIONS: The results of the current study demonstrate that the concurrent administration of CMF and RT is associated with a low risk of serious toxicity and is an acceptable adjuvant regimen for patients with breast carcinoma...
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled studyHelen G Mar Fan
Princess Margaret Hospital and University of Toronto, Ontario, Canada
J Clin Oncol 23:8025-32. 2005..CONCLUSION: Fatigue, menopausal symptoms, and cognitive dysfunction are important adverse effects of chemotherapy that improve in most patients. Hormonal treatment has minimal impact on them...
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinomaBrigette B Y Ma
Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
Cancer 95:2516-23. 2002..Median survival has not been reached. CONCLUSIONS: Our study confirms that GEM is an active and tolerable drug for patients with NPC...
How valid are claims for synergy in published clinical studies?A Ocana
Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Ann Oncol 23:2161-6. 2012..Clinical trials evaluating drug combinations are often stimulated by claims of synergistic interactions in preclinical models. Overuse or misuse of the term synergy could lead to poorly designed clinical studies...
Cytostatic potential of novel agents that inhibit the regulation of intracellular pHP Wong
Department of Medical Biophysics, Princess Margaret Hospital Ontario Cancer Institute, University of Toronto, Toronto, M5G 2M9, Canada
Br J Cancer 87:238-45. 2002..Our results indicate that cariporide and S3705 are selective cytostatic agents under in vitro conditions that reflect the slightly acidic microenvironment found in solid tumours...
pH dependent cytotoxicity of N-dodecylimidazole: a compound that acquires detergent properties under acidic conditionsM J Boyer
Department of Medicine, Ontario Cancer Institute, Toronto, Canada
Br J Cancer 67:81-7. 1993....
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinomaJ S McCarthy
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
Oral Oncol 38:686-90. 2002..In view of the low response rate, accrual was terminated and the trial was aborted...
The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenaseM Yamagata
Department of Medicine and Medical Biophysics, Ontario Cancer Institute Princess Margaret Hospital, Toronto, Canada
Br J Cancer 77:1726-31. 1998....
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinomaMonika K Krzyzanowska
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
Cancer Chemother Pharmacol 60:135-41. 2007..The lack of effective systemic therapies for patients with advanced renal cell carcinoma (RCC) has stimulated interest in evaluating novel treatment strategies for this disease...
Assessing cognitive function in cancer patientsJanette Vardy
Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Support Care Cancer 14:1111-8. 2006..Some patients with cancer suffer cognitive impairment after chemotherapy. A brief, sensitive instrument is required to screen patients for cognitive impairment. In this study, we compare three possible screening instruments...
Long-term outcome of radiation-based conservation therapy for invasive bladder cancerPeter W M Chung
Department of Radiation Oncology, Princess Margaret Hospital, University Health Network and University of Toronto, Toronto, Ontario M5G 2M9, Canada
Urol Oncol 25:303-9. 2007..To report the long-term results and examine factors associated with bladder preservation, risk of relapse, and survival in patients treated with radical radiotherapy for invasive bladder cancer...
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapyJ Vardy
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Ave, Toronto, Ontario, Canada M5G2M9
Br J Cancer 94:1011-5. 2006..A randomised, double-blind crossover trial is underway to determine the effect of dexamethasone on nausea and vomiting, and the impact of side effects of dexamethasone and of nausea and vomiting on quality of life...
The changing face of hormonal therapy for prostate cancerB Seruga
Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Ann Oncol 19:vii79-85. 2008
Doctor's dilemma: incorporating tumor markers into clinical decision-makingChristina M Canil
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, University Health Network, Toronto, Ontario, Canada
Semin Oncol 29:286-93. 2002....
Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort studyMala Bahl
The Samuel Lunenfeld Research Institute and Department of Medicine, Mount Sinai Hospital, Toronto, ON, Canada
Breast Cancer Res Treat 94:135-44. 2005..Here, we examine whether serum levels of total cholesterol (TC) and triglycerides (TG) influence breast cancer outcome...
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenograftsAndrea S Fung
Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
Clin Cancer Res 15:5389-95. 2009..We compared the effects of concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin (mTOR) inhibitor temsirolimus (CCI-779) on tumor cells and xenografts...
Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracilLicun Wu
Division of Experimental Therapeutics and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Ontario, M5G 2M9 Canada
Cancer Res 63:2134-8. 2003..05 for each comparison). Accelerating repopulation after sequential treatments with cyclophosphamide or 5FU can lead to effective drug resistance in the absence of changes in the sensitivity of constituent cells...
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancerHelen G Mar Fan
Princess Margaret Hospital and University of Toronto, 610 University Ave, Suite 5 218, Toronto, Ontario, M5G 2M9, Canada
Support Care Cancer 16:577-83. 2008..Women who receive adjuvant chemotherapy for breast cancer develop fatigue, and a subset reports cognitive impairment. Methylphenidate is reported to improve fatigue and to decrease cognitive impairment in other populations...
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future researchJanette Vardy
Princess Margaret Hospital, Toronto, Ontario, Canada
J Clin Oncol 25:2455-63. 2007..There is evidence that some cancer survivors suffer cognitive impairment after chemotherapy. Determining if a patient has cognitive impairment is challenging, especially because impairment is usually subtle...
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancerJ Vardy
Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Breast Cancer Res Treat 136:143-51. 2012..No other symptom/QOL domains differed significantly. In conclusion, no significant difference was found in patient preference, QOL, or symptoms regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy...
Treatment of cancer with radiation and drugsI F Tannock
Department of Medicine, Princess Margaret Hospital, Toronto, Canada
J Clin Oncol 14:3156-74. 1996..To review the current status and future prospects of combined treatment of cancer with radiation and drugs...
Quality of life and understanding of disease status among cancer patients of different ethnic originN Tchen
Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, Canada M5G 2M9
Br J Cancer 89:641-7. 2003..001 for Italian vs other groups). Performance status was correlated with QoL and most closely related with the extent of disease. Understanding of cultural differences is important for optimal management of patients with cancer...
The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cellsRama Grantab
Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
Cancer Res 66:1033-9. 2006....
Drug resistance and the solid tumor microenvironmentOlivier Tredan
Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
J Natl Cancer Inst 99:1441-54. 2007....
Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapyWu Licun
Division of Experimental Therapeutics and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario M5G 2M9 Canada
Clin Cancer Res 9:4614-8. 2003..Scheduling of short-acting SERMs between courses of chemotherapy has the potential to improve therapeutic index...
Evolution of the randomized controlled trial in oncology over three decadesChristopher M Booth
National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
J Clin Oncol 26:5458-64. 2008..The randomized controlled trial (RCT) is the gold standard for establishing new therapies in clinical oncology. Here we document changes with time in design, sponsorship, and outcomes of oncology RCTs...
The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantroneOlivier Tredan
Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Cancer Res 69:940-7. 2009..This study supports clinical evaluation of AQ4N in combination with conventional anticancer agents, such as mitoxantrone...
Tumor physiology and resistance to chemotherapy: repopulation and drug penetrationAlison J Davis
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
Cancer Treat Res 112:1-26. 2002
The role of systemic chemotherapy in the management of muscle-invasive bladder cancerHelen G Juffs
Princess Margaret Hospital, Ontario, Toronto, Canada
Lancet Oncol 3:738-47. 2002..Other trials should address the role of molecular markers in selecting patients for chemotherapy. Whenever possible, chemotherapy for locally advanced muscle-invasive TCC should be given in the context of a well-designed clinical trial...
"PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancerAisha Lofters
Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Ontario, Canada
J Urol 168:2516-20. 2002..Before receiving PSA results 76% reported some level of anxiety and 15% reported extreme anxiety. CONCLUSIONS: PSA related anxiety represents a substantial problem in patients with metastatic prostate cancer...
Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues?M J Moore
Department of Medicine, Princess Margaret Hospital, Toronto, Canada
Br J Cancer 62:988-91. 1990..We conclude that treatment strategies of urologic oncologists are influenced minimally by opinions of their colleagues, but that the method of using surrogate questionnaires is a valuable aid to the design of clinical trials...
Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: a model for studying host effects on apparent drug resistanceC K Luk
Physics Division, Ontario Cancer Institute, Toronto, Canada
Br J Cancer 58:133-8. 1988..Our results indicate that cyclophosphamide produces only a small effect on the host in this system, but the model is a potentially useful one to investigate the contribution of the host in the acquisition of drug resistance...
Quality of cancer careJ Vardy
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
Ann Oncol 15:1001-6. 2004..Treatment of the whole patient requires attention to communication, and to the management of symptoms such as pain and fatigue. Cancer care must be of high quality and delivered with compassion...
Potential drug interactions and duplicate prescriptions among cancer patientsRachel P Riechelmann
Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
J Natl Cancer Inst 99:592-600. 2007..Cancer patients receive numerous medications, including antineoplastic agents, drugs for supportive care, and medications for comorbid illnesses. Therefore, they are at risk for drug interactions and duplicate prescribing...
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumorsAndrew J Primeau
Division of Applied Molecular Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Clin Cancer Res 11:8782-8. 2005..The technique described here can be adapted to studying the distribution of other drugs within solid tumors and the effect of strategies to modify their distribution...
Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapyLicun Wu
Division of Experimental Therapeutics, Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
Clin Cancer Res 11:8195-200. 2005..The scheduling of short-acting hormonal agents between courses of adjuvant chemotherapy for human breast cancer has potential to improve the outcome of treatment...
Phase II trial of mirtazapine for cancer-related cachexia and anorexiaRachel P Riechelmann
Department of Medical Oncology, University of Toronto, Canada
Am J Hosp Palliat Care 27:106-10. 2010..2 kg); 24% and 6% improved appetite and health-related quality of life (HQOL), respectively. Mirtazapine is a promising agent for the treatment of CRCA...
Management of advanced prostate cancer after first-line chemotherapyDominik R Berthold
Department of Medical Oncology, Princess Margaret Hospital, and University of Toronto, Ontario M5G 2M9, Canada
J Clin Oncol 23:8247-52. 2005....
Sorafenib for metastatic renal cancer: the Princess Margaret experienceRachel P Riechelmann
Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
Am J Clin Oncol 31:182-7. 2008..Grade 3/4 adverse events were reported in 12% of patients. This study presents sorafenib's efficacy and safety in a less selected cohort of patients enrolled in an expanded access program...
Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetingsPhilippe L Bedard
Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
J Clin Oncol 25:3482-7. 2007..To investigate the prevalence of underpowered randomized controlled trials (RCTs) presented at American Society of Clinical Oncology (ASCO) annual meetings...
Chemotherapy-based treatment for castration-resistant prostate cancerBostjan Seruga
Institute of Oncology Ljubljana, Ljubljana, Slovenia
J Clin Oncol 29:3686-94. 2011....
Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian designAlan Tinmouth
Department of Hematology and Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
Transfusion 44:1711-9. 2004..A randomized controlled trial was undertaken to examine the effectiveness of low-dose PLT transfusions and to determine the need for further studies...
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional statusMala Bahl
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
Int J Radiat Oncol Biol Phys 60:1127-36. 2004..The prophylactic insertion of a feeding tube may facilitate therapy completion and weight recovery in some patients...
Cytokines and their relationship to the symptoms and outcome of cancerBostjan Seruga
Division of Medical Oncology, Princess Margaret Hospital, St Michael s Hospital, University of Toronto, Toronto, Canada
Nat Rev Cancer 8:887-99. 2008..However, physical activity might modify cytokine levels and decrease fatigue in patients with cancer, and might also improve their prognosis...
Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancerIgnacio Duran
Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
J Gen Intern Med 21:C6-8. 2006..We discuss the pathogenesis, differential diagnosis, and association of DIC with prostate cancer along with the management of this condition...
Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cellsPhilip Wong
Department of Medical Biophysics and Medical Oncology, Princess Margaret Hospital/Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada
Clin Cancer Res 11:3553-7. 2005..Although these results add to evidence that manipulation of intracellular pH within the acidic environment of solid tumors can influence the effects of chemotherapy, they are too small and inconsistent to warrant clinical evaluation...
Screening trials are even more difficult than we thought they wereHelen G Juffs
J Natl Cancer Inst 94:156-7. 2002
Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure?Anthony M Brade
J Clin Oncol 24:1020-2. 2006
Should screen-detected breast cancers be managed differently?Monika K Krzyzanowska
J Natl Cancer Inst 97:1170-1. 2005
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysisAndrew J Armstrong
Duke Comprehensive Cancer Center, Durham, North Carolina 27705, USA
Clin Cancer Res 13:6396-403. 2007..To develop a prognostic model and nomogram using baseline clinical variables to predict death among men with metastatic hormone-refractory prostate cancer (HRPC)...
Placebo effects in oncologyGisèle Chvetzoff
Department of Medical Oncology, Centre Leon Berard, Lyon, France
J Natl Cancer Inst 95:19-29. 2003..We hypothesized that administration of placebos would improve symptom control and quality of life but would not lead to tumor response...
Drug penetration in solid tumoursAndrew I Minchinton
Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, Canada
Nat Rev Cancer 6:583-92. 2006....
Postoperative radiotherapy for breast cancer: growing evidence for an impact on survivalKatherine A Vallis
J Natl Cancer Inst 96:88-9. 2004
Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone?Christina M Canil
J Natl Cancer Inst 94:1422-3. 2002
Trials in palliative treatment--have the goal posts been moved?Peter Kirkbride
Weston Park Hospital, Sheffield, UK
Lancet Oncol 9:186-7. 2008
Ethics in oncology: consulting for the investment industryJordan Berlin
Vanderbilt University Medical Center, Nashville, TN, USA
J Clin Oncol 25:444-6. 2007..Because these columns are intended to address the concerns of ASCO members, the Committee welcomes suggestions for future topics at vignettes@asco.org. Martin D. Abeloff, MD, Chair, Ethics Committee...
Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovationEric X Chen
JAMA 292:2150-1. 2004
